Metabolic study of GW1516 in equine urine using liquid chromatography/electrospray ionization Q‐Exactive high‐resolution mass spectrometry for doping control
- 14 December 2020
- journal article
- research article
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 35 (5) , e9028
Abstract
Rationale: The use of GW1516, a peroxisome proliferator‐activated receptor δ (PPAR δ) agonist, is strictly prohibited in both horseracing and equestrian competitions. However, little is known about its metabolic fate in horses. To the best of our knowledge, this is the first reported metabolic study of GW1516 in equine urine. Methods: Urine samples obtained from a thoroughbred after nasoesophageal administration with GW1516 were protein‐precipitated and the supernatants were subsequently analyzed by liquid chromatography/electrospray ionization high‐resolution mass spectrometry (LC/ESI‐HRMS) with a Q‐Exactive mass spectrometer. Monoisotopic ions of GW1516 and its metabolites were monitored from the full‐scan mass spectral data of pre‐ and post‐administration samples. A quantification method was developed and validated to establish the excretion profiles of GW1516, its sulfoxide, and its sulfone in equine urine. Results: GW1516 and its nine metabolites [including GW1516 sulfoxide, GW1516 sulfone, 5‐(hydroxymethyl)‐4‐methyl‐2‐(4‐trifluoromethylphenyl)thiazole (HMTT), methyl 4‐methyl‐2‐[4‐(trifluoromethyl)phenyl]‐1,3‐thiazole‐5‐carboxylate (MMTC), 4‐methyl‐2‐[4‐(trifluoromethyl)phenyl]‐1,3‐thiazole‐5‐carboxylic acid (MTTC), and M1 to M4] were detected in post‐administration urine samples. GW1516 sulfoxide and GW1516 sulfone showed the longest detection times in post‐administration urine samples and were therefore recommended as potential screening targets for doping control purposes. Quantitative analysis was also conducted to establish the excretion profiles of GW1516 sulfoxide and GW1516 sulfone in urine. Conclusions: For the purposes of doping control of GW1516, the GW1516 sulfoxide and GW1516 sulfone metabolites are recommended as the target analytes to be monitored in equine urine due to their high specificities, long detection times (1 and 4 weeks, respectively), and the ready availability of their reference materials.Keywords
This publication has 23 references indexed in Scilit:
- Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q‐Exactive high‐resolution mass spectrometryRapid Communications in Mass Spectrometry, 2020
- Detection of prohibited substances in equine hair by ultra‐high performance liquid chromatography–triple quadrupole mass spectrometry – application to doping control samplesDrug Testing and Analysis, 2018
- A simultaneous determination method for 5‐fluorouracil and its metabolites in human plasma with linear range adjusted by in‐source collision‐induced dissociation using hydrophilic interaction liquid chromatography–electrospray ionization–tandem mass spectrometryBiomedical Chromatography, 2016
- A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming miceScientific Reports, 2015
- New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver diseaseExpert Opinion on Pharmacotherapy, 2014
- Effect of PPARβ/δ Agonist on the Placentation and Embryo‐Fetal Development in RatsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2013
- Synthesis, Mass Spectrometric Characterization, and Analysis of the PPARδ Agonist GW1516 and Its Major Human Metabolites: Targets in Sports Drug Testing2012
- Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urineDrug Testing and Analysis, 2012
- Characterization of two major urinary metabolites of the PPARδ-agonist GW1516 and implementation of the drug in routine doping controlsAnalytical and Bioanalytical Chemistry, 2009
- AMPK and PPARδ Agonists Are Exercise MimeticsCell, 2008